Compare NVR Inc. Common Stock (NVR) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NVR Inc. Common Stock vs Stryker Corporation — how do they compare? NVR Inc. Common Stock trades at $5,845.81 (market cap $15.28B), while Stryker Corporation trades at $285.51 (market cap $108.02B). The key difference: Stryker Corporation is far larger — about 7.1× NVR Inc. Common Stock's market cap, and Stryker Corporation pays a 1.25% dividend while NVR Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold NVR Inc. Common Stock for 0 Days and Stryker Corporation for 22 Days on average.
| NVR | SYK | |
|---|---|---|
Market Cap | $15.28B | $108.02B |
Volume | 53,948 | 2,222,698 |
Sector | Consumer Cyclical | Health |
52-Week High | $8.10K | $388.35 |
52-Week Low | $5.56K | $269.75 |
Typical Hold Time | 0 Days | 22 Days |
Enterprise Value | $15.18B | $119.49B |
Dividend Yield | — | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVR trades at $5,797.61, up 0.83% today, with a P/E of 15.07 and P/S of 1.79. Recent earnings missed estimates in Q1 and Q2 2026, with revenue and net income projected to decline in 2026. The stock faces headwinds from margin pressure and softer homebuyer demand, as highlighted by Zacks naming it Bear of the Day on October 9, 2026. Despite this, strong profitability metrics like a 31.54% ROE and consistent cash flow from operations support its financial resilience.
The outlook is cautious due to earnings misses and a projected revenue drop, but the asset-light model and share buybacks provide stability. Risks include mortgage rate sensitivity and competitive pressures, while analyst consensus leans neutral with a $6,550 price target. Patient investors may find value if housing demand recovers.
Stryker (SYK) trades at $282.63, showing minimal daily change. The stock exhibits neutral technical signals with mixed moving averages and oscillators. Fundamentally, the company maintains strong profitability with a 14.43% net income margin and 16.51% ROE. Recent Q2 2026 earnings beat expectations, though Q1 2026 was a miss. Analyst sentiment is strongly bullish with a $365.89 consensus price target, but recent news highlights legal investigations and a manufacturing issue disclosure that caused an 8.8% share drop in early September 2026.
The outlook for SYK is cautiously optimistic. Strong fundamentals and analyst support suggest upside potential, but near-term risks from legal scrutiny and operational challenges could pressure the stock. Investors should weigh robust financial health against headline volatility ahead of Q3 2026 earnings on October 29, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NVR Inc. Common Stock
NVR Inc. is a homebuilder operating through homebuilding and mortgage banking segments, building single-family homes, townhomes, and condominiums under the Ryan Homes, NVHomes, and Heartland Homes brands. It uses a land-light model, acquiring lots through third-party option agreements rather than holding large land inventories, and provides mortgage and title services through NVR Mortgage.
Read more on NVR →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
